Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 135 Carcinoma, Hepatocellular 81 Neoplasms 53 Small Cell Lung Carcinoma 51 Breast Neoplasms 50 Lung Neoplasms 45 Triple Negative Breast Neoplasms 41 Colorectal Neoplasms 39 Melanoma 38 Carcinoma, Transitional Cell 37 Urinary Bladder Neoplasms 33 Neoplasm Metastasis 32 Carcinoma, Renal Cell 30 Ovarian Neoplasms 20 Uterine Cervical Neoplasms 19 Stomach Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 17 Head and Neck Neoplasms 15 Liver Neoplasms 14 Prostatic Neoplasms 13 Glioblastoma 12 Solid Tumors 11 Recurrence 11 Sarcoma 10 Esophageal Neoplasms 10 Pancreatic Neoplasms 9 Lymphoma 9 Kidney Neoplasms 9 Endometrial Neoplasms 9 Mesothelioma, Malignant 8

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × atezolizumab × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡